
Exocrine Pancreatic Insufficiency Treatment Market
Description
Exocrine Pancreatic Insufficiency Treatment Market
The Global Exocrine Pancreatic Insufficiency Treatment Market reached approximately USD 2.7 billion in 2023, with a projected growth rate of 5.6% CAGR from 2024 to 2032. Exocrine pancreatic insufficiency, characterized by a lack of pancreatic enzymes critical for nutrient digestion and absorption, is managed through a combination of medical and dietary approaches. Treatment strategies for EPI aim to reduce symptoms, boost nutrient absorption, and improve the quality of life for those affected by the condition.Significant advancements in diagnostic techniques for EPI are improving detection and supporting more timely, effective treatments. Latest research has aimed at detecting definite biomarkers, which are transforming pancreatic function assessments and facilitating earlier diagnosis. Fecal elastase-1 has emerged as an essential biomarker, with low levels indicating pancreatic insufficiency, enhancing diagnostic precision and contributing to market expansion.The market is segmented by treatment type into nutritional management and pancreatic enzyme replacement therapy (PERT), with the PERT segment leading in market revenue, reaching USD 2.3 billion in 2023. PERT aids in restoring the body’s ability to digest essential nutrients, alleviating common symptoms such as bloating and steatorrhea. By enabling proper absorption of fats, proteins, and carbohydrates, PERT prevents complications associated with EPI, including malnutrition, vitamin deficiencies, and unintended weight loss, significantly improving patients' quality of life.In terms of drug types, the market includes key medications designed for PERT, each offering unique formulations to enhance nutrient absorption and relieve symptoms associated with EPI. With enzymes like lipase, protease, and amylase, these therapies are optimized for efficiency, utilizing enteric-coated capsules to ensure enzymes are effectively released in the small intestine where digestion occurs. These formulations are available in various dosages, allowing for treatment customization based on individual patient requirements.North America accounted for a major share of the EPI treatment market in 2023, with an anticipated growth reaching USD 2.4 billion by 2032. The region benefits from advanced healthcare infrastructure, extensive research initiatives, and broad access to PERT, driving growth in EPI treatment availability. Additionally, comprehensive insurance coverage and well-established healthcare systems in North America enhance patient access to specialized medications and care, further supporting market expansion and improved patient outcomes. As advancements in diagnostic methods and therapeutic options continue to evolve, the global EPI treatment market is expected to see steady growth.
Table of Contents
101 Pages
- Chapter 1 Methodology
- 1.1 Market segmentation
- 1.2 Market definitions
- 1.3 Research design
- 1.4 Market size estimates and calculations
- 1.4.1 Company share analysis
- 1.4.2 Prevalence based approach
- 1.5 Key trends for market estimates
- 1.6 Forecast model
- 1.7 Primary research & validation
- 1.7.1 Primary sources
- 1.7.2 Data mining sources
- 1.7.2.1 Paid sources
- 1.7.2.2 Public sources
- Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis, 2021 - 2032
- 2.2 Treatment trends
- 2.3 Drug type
- 2.4 Symptom trends
- 2.5 Distribution channel trends
- 2.6 Regional trends
- Chapter 3 Exocrine Pancreatic Insufficiency Treatment Market Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of chronic pancreatitis (CP) and cystic fibrosis
- 3.2.1.2 Growing aging population
- 3.2.1.3 Advancements in diagnosis
- 3.2.1.4 Technological advancements in pharmaceutical industry
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of treatment
- 3.2.2.2 Limited awareness and education
- 3.3.1 By treatment
- 3.3.2 By drug type
- 3.3.3 By symptom
- 3.3.4 By distribution channel
- 3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.5 Technology landscape
- 3.6 Pipeline analysis
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
- Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.1.1 AbbVie Inc.
- 4.1.2 Abbott Laboratories
- 4.1.3 Nestlé S.A.
- 4.1.4 Viatris Inc.
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
- Chapter 5 Exocrine Pancreatic Insufficiency Treatment Market, By Treatment
- 5.1 Nutritional management
- 5.2 Pancreatic enzyme replacement therapy (PERT)
- Chapter 6 Exocrine Pancreatic Insufficiency Treatment Market, By Drug Type
- 6.1 Creon
- 6.2 Zenpep
- 6.3 Pancreaze
- 6.4 Viokace
- 6.5 Other drug types
- Chapter 7 Exocrine Pancreatic Insufficiency Treatment Market, By Symptom
- 7.1 Abdominal pain
- 7.2 Constipation
- 7.3 Diarrhea
- 7.4 Fatty stools
- 7.5 Weight loss
- 7.6 Other symptoms
- Chapter 8 Exocrine Pancreatic Insufficiency Treatment Market, By Distribution Channel
- 8.1 Hospital pharmacies
- 8.2 Retail pharmacies
- 8.3 Online pharmacies
- Chapter 9 Exocrine Pancreatic Insufficiency Treatment Market, By Region
- 9.1 North America
- 9.2 Europe
- 9.3 Asia Pacific
- 9.4 Latin America
- 9.5 Middle East and Africa
- Chapter 10 Company Profile
- 10.1 Abbott Laboratories
- 10.1.1 Global overview
- 10.1.2 Business overview
- 10.1.3 Financial data
- 10.1.3.1 Annual sales revenue, 2023-2020 (USD Million)
- 10.1.4 Product landscape
- 10.1.5 SWOT analysis
- 10.2 AbbVie Inc.
- 10.2.1 Global overview
- 10.2.2 Business overview
- 10.2.3 Financial data
- 10.2.3.1 Annual sales revenue, 2023-2020 (USD Million)
- 10.2.4 Product landscape
- 10.2.5 SWOT analysis
- 10.3 Digestive Care, Inc.
- 10.3.1 Global overview
- 10.3.2 Business overview
- 10.3.3 Financial data
- 10.3.4 Product landscape
- 10.3.5 SWOT analysis
- 10.4 Essential Pharma
- 10.4.1 Global overview
- 10.4.2 Business overview
- 10.4.3 Financial data
- 10.4.4 Product landscape
- 10.4.5 SWOT analysis
- 10.5 Nestlé S.A.
- 10.5.1 Global overview
- 10.5.2 Business overview
- 10.5.3 Financial data
- 10.5.3.1 Annual sales revenue, 2023-2020 (USD Million)
- 10.5.4 Product landscape
- 10.5.5 Strategic outlook
- 10.5.6 SWOT analysis
- 10.6 Nordmark Pharma GmbH
- 10.6.1 Global overview
- 10.6.2 Business overview
- 10.6.3 Financial data
- 10.6.4 Product landscape
- 10.6.5 SWOT analysis
- 10.7 Sun Pharmaceutical Industries Ltd
- 10.7.1 Global overview
- 10.7.2 Business overview
- 10.7.3 Financial data
- 10.7.3.1 Annual sales revenue, 2023-2020 (USD Million)
- 10.7.4 Product landscape
- 10.7.5 SWOT analysis
- 10.8 Viatris Inc.
- 10.8.1 Global overview
- 10.8.2 Business overview
- 10.8.3 Financial data
- 10.8.3.1 Annual sales revenue, 2023-2020 (USD Million)
- 10.8.4 Product landscape
- 10.8.5 SWOT analysis
- 10.9 VIVUS LLC
- 10.9.1 Global overview
- 10.9.2 Business overview
- 10.9.3 Financial data
- 10.9.4 Product landscape
- 10.9.5 SWOT analysis
- 10.10 Zentiva Pharma UK Ltd
- 10.10.1 Global overview
- 10.10.2 Business overview
- 10.10.3 Financial data
- 10.10.4 Product landscape
- 10.10.5 SWOT analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.